About Us

At Ironshore Pharmaceuticals & Development, Inc. we use proprietary drug-delivery technology to develop improved versions of existing drug products.

What We Do

Ironshore Pharmaceuticals & Development, Inc. is a biopharmaceutical company whose mission is to develop innovative, patient-centric treatment options, utilizing its proprietary DELEXIS® technology, to improve the lives of patients and caregivers. Based in Grand Cayman, Ironshore is responsible for managing all intellectual property, and directing all research, development and manufacturing activities for its drug candidates. Ironshore is a wholly owned subsidiary of Toronto-based Highland Therapeutics Inc.

Ironshore's lead compound, HLD200 (delayed-release and extended-release methylphenidate) is under development for the treatment of Attention-Deficit/Hyperactivity Disorder, or ADHD. A New Drug Application has been submitted to the U.S. Food and Drug Administration.

Ironshore Office

Controlled Release

Ironshore in the Cayman Islands

Research & Development Headquarters
10 Market Street
Suite 715
Camana Bay, KY1-9006
Cayman Islands

Highland Therapeutics

Highland Therapeutics Inc. is an emerging pharmaceutical company focused on the development and commercialization of proprietary drugs utilizing a proprietary drug delivery system named DELEXIS®. Visit to learn more.

Highland's Main Office

Highland Office

Highland Pharmaceuticals

MaRS Centre, South Tower
101 College St, Suite 200
Toronto, ON Canada M5G 1L7